Volume 9, Number 1—January 2003
Perspective
Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors
W. Michael Scheld*
Table 4
Clinical failures of Streptococcus pneumoniae infection with levofloxacina
| Risk factors | ||||||||
|---|---|---|---|---|---|---|---|---|
| No. of cases |
Age |
Indication |
Coexisting conditions |
Prior FQ use |
Yr |
Ref. |
Country |
|
| 1b |
58 |
Meningitis |
HIV, splenectomy |
NR |
1999 |
62 |
USA |
|
| 3 |
NR |
RTI |
Yes |
1999 |
63 |
USA |
||
| 1 |
63 |
CAP |
COPD |
No |
1999 |
64 |
USA |
|
| 1 |
50 |
CAP |
COPD |
No |
2000 |
65 |
USA |
|
| 1 |
84 |
CAP |
COPD |
Yes-Levo |
2000 |
65 |
USA |
|
| 1 |
53 |
HAP |
none |
No |
2001 |
66 |
USA |
|
| 7 |
39-83
(avg. 63) |
4 CAP
3 AECB |
COPD (5) |
5/7
(4-Lev, 1-Mox) |
2001 |
67 |
USA |
|
| 1 |
37 |
CAP |
none |
No |
1999 |
25 |
Canada |
|
| 1b |
66 |
CAP |
COPD |
Yes-Cip +
Lev |
1999 |
25 |
Canada |
|
| 1 |
80 |
AECB/CAP |
COPD, |
Yes-Cip |
2001 |
25 |
Canada |
|
| 1 |
64 |
CAP |
none |
No |
2000 |
25 |
Canada |
|
| 1 |
50 |
CAP |
COPD |
Yes-Lev |
2001 |
68 |
USA |
|
| 1b |
79 |
CAP |
none |
NO |
1999 |
69 |
USA |
|
| 21 |
||||||||
| Clinical trials |
||||||||
| 13 (7 on 500 mg) |
NR |
AECB |
COPD |
No |
70 |
Neth. |
||
| 4 |
NR |
CAP |
NR |
No |
71 |
USA |
||
| 24 (11) |
||||||||
| Epidemiologic studies |
||||||||
| 16c |
- |
LRTI |
COPD |
Yes-Cip |
1995-96 |
72 |
Canada |
|
| 27d |
- |
LRTI |
COPD (17) |
Yes-Lev |
1998-99 |
73 |
HK |
|
| 43 |
||||||||
| Total | 88 (74 on 500 mg) clinical/bacteriologic failures | |||||||
aFQ, fluoroquinolone; NR, not reported; RTI, respiratory tract infection; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; Lev, levofloxacin; Mox, moxifloxacin; HAP, hospital-acquired pneumonia; AECB, acute exacerbation of chronic bronchitis;
LRTI, lower respiratory tract infection; Cip, ciprofloxacin; Neth, the Netherlands; HK, Hong Kong.
bDeath.
c3 deaths.
d4 deaths.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.